|
|
Debates
| DO GENETIC MARKERS HAVE ANY ADDITIONAL CKINICAL RELEVANCE BEYOND TRADITIONAL CVD
RISK FACTORS? |
| Chairpersons: |
G. Uterman, Austria
Z .Reiner, Croatia |
| PRO |
S. Humphries, UK |
| CON |
C. Janssens, The Netherlands |
| |
| SHOULD WE STILL MEASURE SERUM LIPIDS OR NOT TO ESTIMATE CVD RISK? |
| Chairpersons: |
G. Walldius, Sweden
A.Stalenhoef, The Netherlands |
| PRO |
M. Denke, USA |
| CON |
A. Sniderman, Canada |
| |
|
|
